Quote | Pasithea Therapeutics Corp. (NASDAQ:KTTA)
Last: | $5.075 |
---|---|
Change Percent: | 0.0% |
Open: | $5.18 |
Close: | $5.075 |
High: | $5.18 |
Low: | $5.0631 |
Volume: | 2,612 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Pasithea Therapeutics Corp. (NASDAQ:KTTA)
2024-06-25 12:52:56 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pasithea Therapeutics (NASDAQ: KTTA ) just reported results for the fourth quarter of 2023. Pasithea Therapeutics reported earnings per share of -$4.10. The company di...
MIAMI, June 13, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis typ...
Message Board Posts | Pasithea Therapeutics Corp. (NASDAQ:KTTA)
Subject | By | Source | When |
---|---|---|---|
*Pasithea Therapeutics Investor Camac Partners Reported Purchase of | Zorro | investorshub | 08/20/2022 4:01:55 PM |
MIAMI BEACH, Fla., Aug. 18, 2022 (GLOBE NEWSWIRE) | subslover | investorshub | 08/19/2022 12:23:32 PM |
great volume day yesterday on that news | $treet $inatra | investorshub | 08/12/2022 2:32:41 PM |
what does their balance sheet look like? | Hercules1 | investorshub | 08/12/2022 12:00:04 AM |
Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating | subslover | investorshub | 08/11/2022 12:11:46 PM |
News, Short Squeeze, Breakout and More Instantly...
Pasithea Therapeutics Corp. Company Name:
KTTA Stock Symbol:
NASDAQ Market:
Pasithea Therapeutics Corp. Website:
MIAMI, June 13, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis typ...
-- PAS-004 inhibition of in vitro NRAS cell lines does not plateau in contrast to approved MEK inhibitors -- -- PAS-004 inhibition of in vitro NRAS cell lines is greater than selumetinib and binimetinib and similar to trametinib -- -- PAS-004 shows superior activity versus selumetinib and...